Nasdaq · Healthcare
Scilex Holding Co (SCLX)
As-reported financials and recent SEC filings for Scilex Holding Co, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$30.3M
Net income
$-374.1M
Net margin
—
Diluted EPS
$-36.48
ROE
176.6%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $30.3M | $56.6M | $46.7M | $38.0M | $31.3M |
| Gross profit | $19.7M | $39.9M | $31.1M | $27.2M | $27.7M |
| Operating income | $-346.0M | $-83.4M | $-105.4M | $-50.6M | $-35.8M |
| Net income | $-374.1M | $-72.8M | $-114.3M | $-23.4M | $-88.4M |
| Diluted EPS | $-36.48 | $-8.05 | $-16440.32 | $-2183.48 | $-8605.48 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-07-06
View on EDGAR →S-82026-06-30
View on EDGAR →8-K2026-06-29
View on EDGAR →SCHEDULE 13D/A2026-06-26
View on EDGAR →42026-06-26
View on EDGAR →8-K2026-06-24
View on EDGAR →EFFECT2026-06-11
View on EDGAR →S-32026-06-02
View on EDGAR →Largest Healthcare peers
Go deeper on SCLX
Search Scilex Holding Co’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.